{'fraction_non_alphanumeric': 0.029535864978902954, 'fraction_numerical': 0.0, 'mean_word_length': 5.122580645161291, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Killen discusses NIAID strategy, progress in HIV vaccine research and development. National Institute of Allergy and Infectious Diseases.


 The director of NIAID's Division of AIDS, Jack Killen, M.D., discusses plans and progress in the development of HIV vaccines. Dr. Killen is optimistic that a safe and effective vaccine could be developed. Such vaccines would have very few side effects, provide protection against all HIV subtypes, provide long-lasting protection against all potential routes of infection, be inexpensive to manufacture, and be easily stored and administered anywhere in the world. NIAID's strategy for vaccine development, the role of private industry in this process, scientific obstacles faced, and problems arising from HIV genomic diversity are discussed. Results of vaccine studies, plans for phase III HIV vaccine trials, and risk of infecting volunteers in trials, are outlined, as is the future of HIV vaccinology.
